Document Classification

Section Type: RESULTS

Text: After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15. 0 months for docetaxel-carboplatin and 14. 8 months for paclitaxel-carboplatin ; hazard ratio [HR] docetaxel-paclitaxel = 0. 97, 95 % confidence interval [CI] = 0. 83 to 1. 13 ; P =. 707), overall survival rates at 2 years (64. 2 % and 68. 9 %, respectively ; HR = 1. 13, 95 % CI = 0. 92 to 1. 39 ; P =. 238), and objective tumor (58. 7 % and 59. 5 %, respectively ; difference between docetaxel and paclitaxel = -0. 8 %, 95 % CI = -8. 6 % to 7. 1 % ; P =. 868) and CA-125 (75. 8 % and 76. 8 %, respectively ; difference docetaxel-paclitaxel = -1. 0 %, 95 % CI = -7. 2 % to 5. 1 % ; P =. 794) response rates.